Navigation Links
European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012
Date:12/4/2011

SEATTLE, Dec. 5, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today an update on the status and progress of its European marketing authorization application ("MAA") for Pixuvri. CTI is seeking a license to market Pixuvri in the E.U. for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") who have failed two or more prior lines of therapy. CTI received the CHMP's day 180 list of outstanding issues, which unlike the day 120 letter, contained only one remaining major objection to CTI's MAA and items not deemed to be major issues. CTI plans on submitting its responses to the day 180 list of outstanding issues by December 19, 2011. If the responses satisfy the outstanding objection and the CHMP does not require an oral explanation a positive recommendation on the approval of Pixuvri could be made at the January 19th meeting of the CHMP.

"We believe we have made excellent progress working collegially with the E.U. rapporteurs on addressing items raised in the day 120 list of outstanding issues because we resolved all major objections other than the one major remaining objection in the day 180 letter," stated James A. Bianco,  M.D, CEO of CTI.

To address the remaining major objection, the CHMP required that CTI provide a literature review of mechanisms of rituximab resistance and analyses that demonstrate the efficacy of Pixuvri in patients with prior rituximab treatment, as well as information to address some additional questions that were not deemed to be major issues and could be addressed by additional analyses of currently available data.

On November 29th CTI met with the rapporteurs and team members from the EMA for a clarification meeting at which CTI and its clinical expert presented the results of its literature review, additional supportive analyses regarding the efficacy of pixantrone across response rates and progression free surviv
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
2. Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
3. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
4. X-ray Equipment - Top 5 European Markets
5. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
6. RSB Spine, LLC, Announces European Patent Allowance
7. Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
8. Amgen Statement on European Investor Visit
9. European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive)
10. Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
11. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  ProteinSimple announced today that it has launched ... assay allows users to detect all proteins separated in ... users can analyze proteins without the need for an ... protein analysis as we know it today. First, the Simple ... no messy gels, no transfer tanks, no blots, no ...
(Date:7/28/2014)... Germany and LONDON ... , Collaboration aims to create and commercialize ... guide the use of IRESSA  for non-small cell lung ... on QIAGEN,s FDA-approved  therascreen   EGFR test and is planned ... automated instruments  Project enabled by AstraZeneca master ...
(Date:7/28/2014)... 28, 2014 OmPrompt today ... to help it meet the global demand for ... and logistics. Albion joins Shackleton Ventures. ... Over the past 18 months OmPrompt has underpinned ... management team and its operations. The new funding ...
Breaking Medicine Technology:ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6OmPrompt Funded for Customer Automation Management Market Expansion 2
... GREEN BAY, Wis., Jan. 10, 2012  With increasing demands ... longer hours or shuttling the children to and from ... of a challenge. To make life simpler for shoppers ... its mobile pharmacy app, allowing users to quickly and ...
... Oramed Pharmaceuticals Inc. (OTCBB:ORMP) ( http://www.oramed.com ... today that it has filed a provisional patent application ... a combination therapy of its lead compound, ORMD-0801 in ... no such approved combination product available on the market ...
Cached Medicine Technology:Shopko Launches Mobile Pharmacy App to Maximize Customer Convenience 2Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes 2Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes 3
(Date:7/28/2014)... The Oakwood Foundation celebrated a major gift this ... PC that will benefit each community we serve for ... The HBWS group is among the Foundation’s largest physician ... donations. Through their latest gift, they will be one ... Classic for the next 6 years; provide state-of-the-art technology ...
(Date:7/28/2014)... meal you,ve ordered at a restaurantor when something ... your brain. , These waves are called ... cellsboth excitatory and inhibitoryplaying together in an orchestrated ... waves have been associated with higher-level brain function, ... to schizophrenia, Alzheimer,s disease, autism, epilepsy and other ...
(Date:7/28/2014)... By Amy Norton ... -- Tonsillectomies are commonly done to relieve sleep apnea in ... speed kids, weight gain -- especially if they,re already overweight. ... a risk factor for a range of health problems -- ... for kids who need it. Instead, they said, doctors ...
(Date:7/28/2014)... July 28, 2014 UT Southwestern Medical Center ... and irreversibly interferes with the activity of a ... tumors. , The molecule, SML-8-73-1 (SML), interferes with ... oncogene homolog. The gene produces proteins called K-Ras ... can result in normal cells dividing uncontrollably and ...
(Date:7/28/2014)... July 28, 2014 Lourdes Health System ... access and reduced wait times for veterans needing medical ... systems in the state—and the only one in Camden, ... Patient-Centered Community Care program (PC3). PC3 gives veterans access ... hospital cannot provide services due to lack of available ...
Breaking Medicine News(10 mins):Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3
... coronary artery , THURSDAY, Feb. 11 (HealthDay News) -- Former ... Thursday evening in a New York City hospital after he ... , The 63-year-old Clinton, who underwent quadruple bypass surgery in ... reports. , "Today President Bill Clinton was admitted to ...
... , CHICAGO , Feb. 11 ... of Frank Corbett , founder of Frank J. Corbett , ... "Frank was a pioneer in our industry, a legend, a leader for ... CEO, Scott D. Cotherman . "His passion and drive for our industry ...
... , CHICAGO , Feb. 11 The ... proud to announce the selection of attorney Jeffrey Schlapp to ... ® and Chicago Magazine 02/2010 . , When it ... nursing home industry itself on behalf of the injured becomes a game-changer. ...
... children with asthma often recognize signs that their child is ... until the attack occurs, researchers at Washington University School of ... published in the Annals of Allergy, Asthma and Immunology, ... thus relieve a child,s symptoms, possibly reduce the extent of ...
... ... charity Landlife and is giving away free wild flower seeds. Simply request free samples from ... 1st April through until May. , ... (PRWEB) February 13, 2010 -- The online window blinds retailer, Tuiss.co.uk , has ...
... aren,t conclusive, researchers say , THURSDAY, Feb. 11 (HealthDay ... that eating dark chocolate appears to lower your risk of ... , But the findings, based on a review of ... is good for your heart. And dietitians say too much ...
Cached Medicine News:Health News:Ex-President Clinton Undergoes Heart Procedure 2Health News:Corbett Accel Healthcare Group Mourns Passing of Founder Frank J. Corbett 2Health News:Corbett Accel Healthcare Group Mourns Passing of Founder Frank J. Corbett 3Health News:Beware the Gentle Man With Unique Knowledge: The Passion and Skill of a Rising Star 2Health News:Parents often wait too long to treat children's asthma symptoms 2Health News:Parents often wait too long to treat children's asthma symptoms 3Health News:Go Wild with Blinds Retailer Tuiss.co.uk and Environmental Charity Landlife 2Health News:Dark Chocolate May Lower Stroke Risk 2
... The design of the Hi-Top ... to be held back in ... shoe counter. The front is ... and compression on the toes. ...
... semi-rigid post op shoe is ideal for ... breathable upper will keep your patient both ... closure provides even tension and compression. The ... support for your patient. The black TPR ...
Comfortably positions the affected foot at 90 to provide continuous and effective stretching of the plantar fascia and Achilles Tendon...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: